Evidence map›Paper›PMID 40814369›Full record

ArticleAmerican journal of cancer research2025

Vulvar dermatofibrosarcoma protuberans: a case series.

Chuan Xie, Yangmei Shen

Abstract readCase Reports
In one paragraph

Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Chuan XieDepartment of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University Chengdu, Sichuan, P. R. China.
Yangmei ShenKey Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education Chengdu, Sichuan, P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dermatofibrosarcoma protuberans (DFSP) is a rare, superficial low - to intermediate-grade sarcoma that typically presents as an asymptomatic slow-growing indurated dermal plaque. Although DFSP has a relatively high local recurrence rate, distant metastasis is rare. DFSP primarily occurs on the trunk and extremities but is seldom reported in the vulva. Due to its rarity, the clinical characteristics, pathological diagnosis, prognosis, and optimal management of vulvar DFSP remain poorly characterized. We retrospectively analyzed vulvar DFSP cases from our institution (January 2010 - January 2023). Clinical data and follow-up were obtained from hospital records, and imaging studies were reviewed via the picture archiving and communication system. Seven patients were included, with a median symptom-onset age of 44.3 years (range, 27-73). Patients typically presented with firm, asymptomatic masses. The labia majora was most commonly affected (n = 6, 85.7%). Tumor size averaged 4.3 cm (range, 2.0-6.5). All patients underwent excisional biopsy followed by wide local excision; none received lymphadenectomy. Surgical margins were documented in six patients, with negative margins achieved in five after initial wide excision. Over a mean follow-up of 27.3 months (range, 12-54), one patient (14.3%) experienced local recurrence. No recurrence occurred in patients with negative margins. Vulvar DFSP predominantly affects young and middle-aged women, manifesting as vulvar masses of variable size. Wide local excision is the primary treatment. While vulvar DFSP has a propensity for local recurrence, widely negative margins appear protective. Long-term follow-up is recommended to monitor for recurrence.

Indexed as

case seriesDermatofibrosarcoma protuberansMohs micrographic surgeryvulvawide local excision

Identifiers

PMID40814369
PMCPMC12344167

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.